Holen Sie sich die Stockscreener-App
7.18
0.00%
0.00
Handel nachbörslich:
7.30
0.12
+1.67%
Schlusskurs vom Vortag:
$7.18
Offen:
$7.25
24-Stunden-Volumen:
3,960
Relative Volume:
0.02
Marktkapitalisierung:
$4.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.28M
KGV:
-1.2914
EPS:
-5.56
Netto-Cashflow:
$-7.99M
1W Leistung:
-2.58%
1M Leistung:
-19.24%
6M Leistung:
-38.02%
1J Leistung:
-60.44%
1-Tages-Spanne:
$7.05
$7.2906
1-Wochen-Bereich:
$6.7479
$7.4799
52-Wochen-Spanne:
$5.01
$54.95
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Firmenname
Quoin Pharmaceuticals Ltd Adr
Sektor
Branche
Telefon
97299741444
Adresse
23 HATA'AS STREET, KFAR SABA
Vergleichen Sie QNRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
7.18 | 4.14M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Quoin Pharmaceuticals Ltd Adr Aktie (QNRX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals releases second episode of ‘Living with Netherton’ series - TipRanks
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com India
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com India
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment By Investing.com - Investing.com South Africa
What Is Going On With Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX)? - stocksregister.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles By Investing.com - Investing.com South Africa
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com India
Quoin seeks patent for skin disease treatment QRX003 By Investing.com - Investing.com South Africa
Quoin seeks patent for skin disease treatment QRX003 - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles By Investing.com - Investing.com South Africa
NVIDIA Corp (NVDA) Shares Up Despite Recent Market Volatility - The News Heater
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com India
Is Energy Services of America Corp (NASDAQ: ESOA) Poised For Further Gains At A 45.82% Distance From The Low? - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
PDD Holdings Inc ADR (NASDAQ: PDD): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Why Should You Invest In Castellum Inc (AMEX: CTM)? - Marketing Sentinel
FTAI Infrastructure Inc (NASDAQ:FIP) Shares Dropped -1.13% In A Week. Can It Continue Rising? - Marketing Sentinel
Capricor Therapeutics Inc (NASDAQ:CAPR) Decline -1.05%, More Rally Possible - Marketing Sentinel
Earnings call transcript: Quoin Pharmaceuticals Q4 2023 sees stock volatility - Investing.com
AST SpaceMobile Inc (ASTS) Investors Will See A Big Return Again - Marketing Sentinel
Finanzdaten der Quoin Pharmaceuticals Ltd Adr-Aktie (QNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quoin Pharmaceuticals Ltd Adr-Aktie (QNRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.45 |
555,556 |
250,000 |
602,808 |
| Dunn Gordon | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.45 |
122,221 |
54,999 |
151,077 |
| Culverwell Anthony James | Director |
Dec 23 '24 |
Buy |
0.45 |
100,000 |
45,000 |
100,317 |
| Dunn Gordon | Chief Financial Officer |
Sep 10 '24 |
Buy |
0.81 |
20,000 |
16,200 |
28,856 |
| Dunn Gordon | Chief Financial Officer |
Sep 09 '24 |
Buy |
0.79 |
8,856 |
7,005 |
8,856 |
| Carter Denise P. | Chief Operating Officer |
Sep 04 '24 |
Buy |
0.78 |
31,813 |
24,912 |
47,092 |
| Carter Denise P. | Chief Operating Officer |
Sep 03 '24 |
Buy |
0.65 |
5,922 |
3,825 |
15,279 |
| Myers Michael | Chief Executive Officer |
Sep 04 '24 |
Buy |
0.77 |
37,094 |
28,421 |
47,252 |
| Myers Michael | Chief Executive Officer |
Sep 03 '24 |
Buy |
0.62 |
800 |
495 |
10,158 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):